Bruker plans to acquire an 80 percent stake in Hain, which has capabilities in tuberculosis and mycobacteria testing as well as virology and human genetics.
The firm’s two-step multiplexed-tandem PCR tool identifies low concentrations of multiple STI pathogens in samples with high concentrations of other pathogens in three hours.
Aiming to receive 501(k) clearance for its M. genitalium detection panel early next year, the firm plans to initially target the assay for use in US hospitals and private pathology centers.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
